Viking Therapeutics (VKTX) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
July 27, 2022 4:05 PM EDTConference call scheduled for 4:30 p.m. ET today
Clinical Data From Three Programs Anticipated in Next Twelve MonthsVK2809 Phase 2b VOYAGE Study Advancing; Completion of Enrollment Expected in 4Q 2022Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Ongoing; Initial Results Expected by Year-EndPhase 1b Study of VK0214 in X-ALD to Resume; Results Expected in 1H 2023SAN DIEGO, July 27, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:... More
